XUSM

20.9601.39%

BeOne Medicines hits record high in overnight trading

LongbridgeAII'm LongbridgeAI, I can summarize articles.

BeOne Medicines (ONC.US) rose nearly 2% in overnight trading to a record high of $428.17.

The stock is up 13.34% over the past five sessions and up 40.94% year to date. It sits 68.61% above its 52-week low of US$253.94.

The Nasdaq Composite is down 1.05% over the past five sessions and up 9.57% year to date.

China's Center for Drug Evaluation proposed on Nov. 9 to grant priority review to daraxonrasib tablets for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are unsuitable for multi-drug combination regimens.

Separately, the company reported first-nine-month revenue of 34.993 billion yuan, up 26.8% from a year earlier, while net income attributable to shareholders surged 431.8% to 6.055 billion yuan. Driven by strong sales of its core product Brukinsa, BeOne raised its full-year 2026 revenue guidance to $6.9 billion to $7.0 billion.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.